Which Form?

Best Form of HRT & Menopause

Short answer

Form verdict: Leaning for

Transdermal estradiol with micronized progesterone is the preferred form of menopause hormone therapy.

Based on what researchers say in public interviews on YouTube and on the studies Precis has read. Not medical advice. Always consult your healthcare provider before starting, stopping, or changing any supplement.

HRT & Menopause forms compared

One row per form claim. Each verdict is worked out from every counted mention: a researcher on tape or a study.

Claim Studies Researchers Verdict
Transdermal estradiol with micronized progesterone is the preferred form of menopause hormone therapy. 27 counted of 33 read 5 counted of 16 on tape Leaning for

positive partly neutral negative Each researcher and each study counts once per claim, however often they come up.

Transdermal estradiol with micronized progesterone is the preferred form of menopause hormone therapy.

Leaning for

32 sources: 17 positive, 10 partly, 5 negative.

Researchers say

5 partly

Studies show

17 positive, 5 partly, 5 negative

27 papers we read

16 more not counted · see why
Show the receipts from 32 sources
  1. Trial or observed group, Lancet, 2003, PMID 12927428 Study · positive

    Estimated risk for VTE in current users of oral ERT compared with transdermal ERT users was 4.0 (1.9-8.3).

  2. Trial or observed group, Circulation, 2005, PMID 16301339 Study · positive

    Oral but not transdermal estrogen was associated with an increased risk of VTE (odds ratio [OR], 4.3; 95% CI, 2.6 to 7.2; and OR, 1.2; 95% CI, 0.8 to 1.7, respectively).

  3. Trial or observed group, J Thromb Haemost, 2006, PMID 16706969 Study · positive

    Oral, not transdermal, estrogen was associated with an increased VTE risk (OR = 4.5; 95% CI: 2.6-7.7 and OR = 1.1; 95% CI: 0.7-1.7, respectively).

  4. Pooled analysis, BMJ, 2008, PMID 18495631 Study · positive

    Meta-analysis of observational studies showed that oral oestrogen but not transdermal oestrogen increased the risk of venous thromboembolism.

  5. Other primary study, J Thromb Haemost, 2010, PMID 20230416 Study · positive

    The risk of VTE was not increased with current use of transdermal estrogen alone (RR 1.01; 95% CI, 0.89-1.16) or combined with a progestogen (RR 0.96; 95% CI, 0.77-1.20), or with current use of tibolone (RR 0.92; 95% CI: 0.77-1.10), relative to non-use.

  6. Other primary study, Menopause, 2011, PMID 21178641 Study · positive

    Oral but not transdermal estrogens are associated with a higher risk of recurrent VTE among postmenopausal women.

  7. Other primary study, Menopause, 2011, PMID 21775912 Study · positive

    After adjustment for confounding factors, the incidence of venous thromboembolism remained significantly lower for estradiol transdermal system users than for estrogen-only hormone therapy users.

  8. Other primary study, J Thromb Haemost, 2012, PMID 22963114 Study · positive

    RRs in current vs. never users at last reporting varied by HT formulation: the risk was significantly greater for oral estrogen-progestin than oral estrogen-only therapy (RR = 2.07 [95%CI, 1.86-2.31] vs. 1.42 [1.21-1.66]), with no increased risk with transdermal estrogen-only therapy (0.82 [0.64-1.06]).

  9. Trial or observed group, J Thromb Haemost, 2013, PMID 23136837 Study · positive

    Non-oral HT did not increase the risk of VT: OR 1.1 (0.6-1.8).

  10. Other primary study, Menopause, 2016, PMID 27023862 Study · positive

    Transdermal estrogen combined with progestogen was not associated with VTE risk (crude and imprecise ORs ranging from 0.87 to 1.16).

  11. Other primary study, Stroke, 2017, PMID 28626058 Study · positive

    We found no risk of stroke with transdermal application and a reduced risk with vaginal estrogen.

  12. Trial or observed group, BMJ, 2019, PMID 30626577 Study · positive

    Transdermal preparations were not associated with risk of venous thromboembolism, which was consistent for different regimens (overall adjusted odds ratio 0.93, 95% confidence interval 0.87 to 1.01).

  13. Pooled analysis, Sci Rep, 2020, PMID 33244065 Study · positive

    Routes of administration Oral 9 1.41 (1.19–1.67) 72.5 < 0.01 Non-oral 7 0.81 (0.60–1.09) 70.8 < 0.01

  14. Systematic review, Arch Gynecol Obstet, 2023, PMID 35713694 Study · positive

    VTE risk can be considered the clearest and strongest clinical difference between the two administration routes, supporting the transdermal HRT as safer than the oral administration route.

  15. Other primary study, Climacteric, 2022, PMID 36218141 Study · positive

    The risk of PE was significantly increased in users of oral but not transdermal MHT, with the highest risk in first ever users of oral estrogen combined with medroxyprogesterone acetate.

  16. Other primary study, Res Pract Thromb Haemost, 2023, PMID 37193125 Study · positive

    For exposures within 60 days, oral MHT risk was almost twice as high as transdermal MHT (OR = 1.92; 95% CI, 1.43-2.60); transdermal MHT did not elevate risk compared with no exposure (unopposed OR = 0.70; 95% CI, 0.59-0.83; combined OR = 0.73; 95% CI, 0.56-0.96).

  17. Other primary study, BMJ, 2026, PMID 42778212 Study · positive

    No increased thrombotic risks were observed with transdermal therapy.

  18. Dr. Mary Claire Haver Video · partly · 2 mentions

    on Huberman Lab, at 1:21:26 · partly · Opinion

    “for that reason I tend to go with the non-oral formulations to avoid that risk”

    on The Diary Of A CEO, at 52:41 · partly · Opinion

    “if they avoid oral estrogen and go with a non-oral form like the patch or the ring or or even a pellet”

  19. Dr. Peter Attia, on FoundMyFitness, at 2:53:06 Video · partly · Opinion

    “our Preferred Product is an estradiol patch”

  20. Dr Sharon Malone, on The Dr. Hyman Show, at 1:02:00 Video · partly · Opinion

    “um that a a transermal may be preferable”

  21. Cynthia Guyer, on The Dr. Hyman Show, at 18:29 Video · partly · Opinion

    “So I tend to use the transdermal because I think it's better tolerated”

  22. Gayatri Devi, on The Drive, at 1:49:43 Video · partly · Opinion

    “I actually prefer transermal in a you know either a gel or a patch”

  23. Other primary study, Int J Cancer, 2005, PMID 15551359 Study · partly

    The risk was significantly greater (p <0.001) with HRT containing synthetic progestins than with HRT containing micronized progesterone, the RRs being 1.4 [1.2-1.7] and 0.9 [0.7-1.2], respectively.

  24. Trial or observed group, Circulation, 2007, PMID 17309934 Study · partly

    In addition, our data suggest that norpregnane derivatives may be thrombogenic, whereas micronized progesterone and pregnane derivatives appear safe with respect to thrombotic risk.

  25. Other primary study, Breast Cancer Res Treat, 2008, PMID 17333341 Study · partly

    This study found no evidence of an association with risk according to the route of estrogen administration (oral or transdermal/percutaneous).

  26. Trial or observed group, BMJ, 2010, PMID 20525678 Study · partly

    The risk of stroke was not increased with use of low oestrogen dose patches (rate ratio 0.81(0.62 to 1.05)) compared with no use, whereas the risk was increased with high dose patches (rate ratio 1.89 (1.15 to 3.11)).

  27. Trial or observed group, Menopause, 2014, PMID 24045672 Study · partly

    In direct comparisons, various HT doses and regimens are associated with similar rates of cardiovascular events and all-cause mortality.

  28. Other primary study, Maturitas, 2006, PMID 16040209 Study · negative

    No difference in risk was seen between current and past use, oral and transdermal HRT or between different regimens (p>0.44).

  29. Trial or observed group, Am J Epidemiol, 2014, PMID 25008104 Study · negative

    In conclusion, micronized progesterone and, to a lesser extent, dydrogesterone at the doses used in France may not be sufficient to prevent estrogen-induced endometrial cancers.

  30. Other primary study, Menopause, 2021, PMID 34313612 Study · negative

    Among women veterans, the risk of VTE was similar in users of oral CEE, oral E2, and transdermal E2.

  31. Other primary study, BJOG, 2024, PMID 38465460 Study · negative

    After adjusting for confounding factors, an increased risk of CVD was observed with the administration of tibolone (hazard ratio, HR 1.143, 95% CI 1.117-1.170), oral estrogen (HR 1.246, 95% CI 1.198-1.295) or transdermal estrogen (HR 1.289, 95% CI 1.066-1.558), compared with the non-MHT group; the risk was based on an increased risk of stroke.

  32. Other primary study, BMJ, 1997, PMID 9081000 Study · negative

    No major risk differences were observed between users of low and high doses of oestrogens, unopposed and opposed treatment, and oral and transdermal preparations.

More on HRT & Menopause